DZD9008 is a new medication being tested to see how well it works against a specific type of lung cancer. This type of lung cancer has a particular genetic change called the EGFR Exon 20 insertion mutation. The medication is designed to target and block the effects of this mutation, which may help stop the cancer from growing or spreading. Patients in the trial will receive this medication to see if it can effectively treat their cancer compared to other treatments.

Platinum-Based Doublet Chemotherapy is a standard treatment for certain types of lung cancer. It involves using two chemotherapy drugs together, one of which is a platinum-based drug. These drugs work by killing cancer cells or stopping them from growing. In this trial, this combination is used as a comparison to see if the new medication, DZD9008, is more effective in treating lung cancer with the EGFR Exon 20 insertion mutation.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation – This type of lung cancer is characterized by the presence of a specific genetic mutation in the epidermal growth factor receptor (EGFR) gene, known as the Exon 20 insertion mutation. It is a form of non-small cell lung cancer (NSCLC) that has either spread locally within the lung or to other parts of the body. The mutation leads to abnormal cell growth and division, contributing to cancer progression. As the disease advances, it can cause symptoms such as persistent cough, chest pain, and difficulty breathing. The progression of this cancer type is influenced by the mutation, which can affect how the cancer cells respond to certain treatments. Understanding the mutation is crucial for determining the most effective therapeutic approach.